NCT04393675View on ClinicalTrials.gov

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

March 31, 2022

Conditions
Uremic Pruritus
Interventions
DRUG

LT5001

Administered twice daily

DRUG

Placebo

Administered twice daily

Trial Locations (1)

Unknown

RECRUITING

China Medical University Hospital, Taichung

Sponsors
All Listed Sponsors
lead

Lumosa Therapeutics Co., Ltd.

INDUSTRY